Literature DB >> 21904635

Dynamics of early histopathological changes in GVHD after busulphan/cyclophosphamide conditioning regimen.

Sulaiman Al-Hashmi1, Zuzana Hassan, Behnam Sadeghi, Björn Rozell, Moustapha Hassan.   

Abstract

Hematopoietic stem cell transplantation (HSCT) is a curative treatment for otherwise incurable diseases. Conditioning regimen is an important part of HSCT and consists of chemotherapy with or without irradiation. Conditioning exerts myelosuppressive, immunosuppressive and antitumor effects, but also contributes to HSCT-related complications including graft-versus-host disease (GVHD). Since almost 50% of the transplanted patients are conditioned with cytostatics without irradiation, we developed and characterized a GVHD mouse model following conditioning with busulphan and cyclophosphamide. Recipient Balb/c female mice were treated with busulphan (20 mg/kg/day for 4 days) and cyclophosphamide (100 mg/kg/day for two days). After one day of rest, recipient mice were transplanted with 2×10(7) bone marrow and 3×10(7) spleen cells from male C57BL/6 (allogeneic group) or female Balb/c (syngeneic/control group) mice. The allogeneic, but not syngeneic transplanted mice developed GVHD. Histopathology of the major internal organs (liver, pancreas, spleen, lungs, heart and kidney) was examined before conditioning start, after conditioning's end and 5, 7 and 21 days after transplantation using hematoxylin-eosin staining. Decreased spleen cellularity and diminished glycogen content in the liver were observed after conditioning regimen. Histopathological changes such as vasculitis, inflammation and apoptotic cell forms in liver, spleen, pancreas, lungs and heart were observed in allogeneic transplanted mice, however, only hypocellular spleen and extramedullar hematopoiesis were detected in syngeneic transplanted animals. No morphological changes were observed in kidney in either HSCT setting. This is the first study describing early histopathological changes after conditioning regimen with busulphan/cyclophosphamide and dynamics of GVHD development in several major internal organs.

Entities:  

Keywords:  Graft-versus-host disease; busulphan; conditioning regimen; cyclophosphamide; hematopietic stem cell transplantation; mouse

Mesh:

Substances:

Year:  2011        PMID: 21904635      PMCID: PMC3160611     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  26 in total

1.  Histopathologic sequence of events in adult mice undergoing lethal graft-versus-host reaction developed across H-2 and/or non-H-2 histocompatibility barriers.

Authors:  H Rappaport; A Khalil; O Halle-Pannenko; L Pritchard; D Dantchev; G Mathé
Journal:  Am J Pathol       Date:  1979-07       Impact factor: 4.307

2.  Busulphan lung: histopathology.

Authors:  P S Hasleton
Journal:  Thorax       Date:  1970-03       Impact factor: 9.139

3.  Nuclear magnetic resonance of hepatic graft-versus-host disease in mice.

Authors:  D D Blatter; J M Crawford; J L Ferrara
Journal:  Transplantation       Date:  1990-12       Impact factor: 4.939

4.  The pancreas in acute graft versus host disease in man.

Authors:  A K Foulis; M A Farquharson; G E Sale
Journal:  Histopathology       Date:  1989-02       Impact factor: 5.087

5.  T cell infiltration and chemokine expression: relevance to the disease localization in murine graft-versus-host disease.

Authors:  J Y New; B Li; W P Koh; H K Ng; S Y Tan; E H Yap; S H Chan; H Z Hu
Journal:  Bone Marrow Transplant       Date:  2002-06       Impact factor: 5.483

6.  Changes in Ia expression in mouse kidney during acute graft-vs-host disease.

Authors:  A Wadgymar; J Urmson; R Baumal; P F Halloran
Journal:  J Immunol       Date:  1984-04       Impact factor: 5.422

7.  Pathology of high dose intermittent cyclophosphamide therapy.

Authors:  R E Slavin; J C Millan; G M Mullins
Journal:  Hum Pathol       Date:  1975-11       Impact factor: 3.466

8.  Busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study.

Authors:  F B Petersen; C D Buckner; F R Appelbaum; R A Clift; J E Sanders; W I Bensinger; R Storb; R P Witherspoon; K M Sullivan; S I Bearman
Journal:  Bone Marrow Transplant       Date:  1989-11       Impact factor: 5.483

9.  Cardiotoxicity associated with high-dose cyclophosphamide therapy.

Authors:  J S Gottdiener; F R Appelbaum; V J Ferrans; A Deisseroth; J Ziegler
Journal:  Arch Intern Med       Date:  1981-05

10.  Expansion and activation kinetics of immune cells during early phase of GVHD in mouse model based on chemotherapy conditioning.

Authors:  Behnam Sadeghi; Suleiman Al-Hashmi; Zuzana Hassan; Bjorn Rozell; Hernan Concha; Carin Lundmark; Kjell-Olov Grönvik; Manuchehr Abedi-Valugerdi; Moustapha Hassan
Journal:  Clin Dev Immunol       Date:  2010-12-21
View more
  6 in total

1.  Accelerated ovarian aging in mice by treatment of busulfan and cyclophosphamide.

Authors:  Yan Jiang; Jing Zhao; Hui-jing Qi; Xiao-lin Li; Shi-rong Zhang; Daniel W Song; Chi-yang Yu; Jian-gang Gao
Journal:  J Zhejiang Univ Sci B       Date:  2013-04       Impact factor: 3.066

2.  A preclinical acute GVHD mouse model based on chemotherapy conditioning and MHC-matched transplantation.

Authors:  K Riesner; M Kalupa; Y Shi; S Elezkurtaj; O Penack
Journal:  Bone Marrow Transplant       Date:  2015-11-23       Impact factor: 5.483

3.  Busulphan-cyclophosphamide cause endothelial injury, remodeling of resistance arteries and enhanced expression of endothelial nitric oxide synthase.

Authors:  Sulaiman Al-Hashmi; Piet J M Boels; Fahad Zadjali; Behnam Sadeghi; Johan Sällström; Kjell Hultenby; Zuzana Hassan; Anders Arner; Moustapha Hassan
Journal:  PLoS One       Date:  2012-01-27       Impact factor: 3.240

4.  Immunosuppressive mechanisms of human bone marrow derived mesenchymal stromal cells in BALB/c host graft versus host disease murine models.

Authors:  Joseph Delano Robles; Yin Ping Liu; Jiamin Cao; Zheng Xiang; Yin Cai; Michael Manio; Eva Hc Tang; Godfrey Chi-Fung Chan
Journal:  Exp Hematol Oncol       Date:  2015-04-30

Review 5.  Cyclosporin A: A Repurposable Drug in the Treatment of COVID-19?

Authors:  Christian A Devaux; Cléa Melenotte; Marie-Dominique Piercecchi-Marti; Clémence Delteil; Didier Raoult
Journal:  Front Med (Lausanne)       Date:  2021-09-06

6.  Pilot Safety Evaluation of a Novel Strain of Bacteroides ovatus.

Authors:  Huizi Tan; Zhiming Yu; Chen Wang; Qingsong Zhang; Jianxin Zhao; Hao Zhang; Qixiao Zhai; Wei Chen
Journal:  Front Genet       Date:  2018-11-06       Impact factor: 4.599

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.